About: A Neutralization Epitope in the Hepatitis C Virus E2 Glycoprotein Interacts with Host Entry Factor CD81

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: A Neutralization Epitope in the Hepatitis C Virus E2 Glycoprotein Interacts with Host Entry Factor CD81 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	A Neutralization Epitope in the Hepatitis C Virus E2 Glycoprotein Interacts with Host Entry Factor CD81
Creator	Alter, Harvey Deng, Lu Elrod, Elizabeth Grakoui, Arash Harman, Christine Liu, Peter Struble, Evi Yan, Hailing Zhang, Pei Zhao, Zhong Zhong, Lilin Li, Ma Luisa Virata-Theimer, Maria
source	PMC
abstract	The identification of a specific immunogenic candidate that will effectively activate the appropriate pathway for neutralizing antibody production is fundamental for vaccine design. By using a monoclonal antibody (1H8) that neutralizes HCV in vitro, we have demonstrated here that 1H8 recognized an epitope mapped between residues A524 and W529 of the E2 protein. We also found that the epitope residues A524, P525, Y527 and W529 were crucial for antibody binding, while the residues T526, Y527 and W529 within the same epitope engaged in the interaction with the host entry factor CD81. Furthermore, we detected “1H8-like” antibodies, defined as those with amino acid-specificity similar to 1H8, in the plasma of patients with chronic HCV infection. The time course study of plasma samples from Patient H, a well-characterized case of post-transfusion hepatitis C, showed that “1H8-like” antibodies could be detected in a sample collected almost two years after the initial infection, thus confirming the immunogenicity of this epitope in vivo. The characterization of this neutralization epitope with a function in host entry factor CD81 interaction should enhance our understanding of antibody-mediated neutralization of HCV infections.
has issue date	2014-01-06(xsd:dateTime)
bibo:doi	10.1371/journal.pone.0084346
bibo:pmid	24400084
has license	cc0
sha1sum (hex)	8a5accd8df7fcfcef5fb8b467e2cc8caa7c631a4
schema:url	https://doi.org/10.1371/journal.pone.0084346
resource representing a document's title	A Neutralization Epitope in the Hepatitis C Virus E2 Glycoprotein Interacts with Host Entry Factor CD81
has PubMed Central identifier	PMC3882236
has PubMed identifier	24400084
schema:publication	PLoS One
resource representing a document's body	covid:8a5accd8df7fcfcef5fb8b467e2cc8caa7c631a4#body_text
is schema:about of	named entity 'production' named entity 'epitope' named entity 'protein' named entity 'mapped' named entity 'FACTOR' named entity 'HAVE' named entity 'HERE' named entity 'SPECIFIC' named entity 'IN VITRO' covid:arg/8a5accd8df7fcfcef5fb8b467e2cc8caa7c631a4 named entity 'EPITOPE' named entity 'MONOCLONAL ANTIBODY' named entity 'DEMONSTRATED' named entity 'HOST' named entity 'CD81' named entity 'GLYCOPROTEIN' named entity 'ENTRY' named entity 'EPITOPE' named entity 'CANDIDATE' named entity 'PATHWAY' named entity 'MAPPED' named entity 'APPROPRIATE' named entity 'USING' named entity 'IDENTIFICATION' named entity 'NEUTRALIZING ANTIBODY' named entity 'ANTIBODY PRODUCTION' named entity 'IMMUNOGENIC' named entity 'E2 PROTEIN' named entity 'HEPATITIS C VIRUS E2' named entity 'HCV' named entity 'ACTIVATE' named entity 'VACCINE DESIGN' named entity 'specific' named entity 'candidate' named entity 'protein' named entity 'vaccine design' named entity 'HCV' named entity 'CD81' named entity 'antibody' named entity 'supernatant' named entity 'highly conserved' named entity 'lysed' named entity 'luciferase' named entity 'antibody' named entity 'immunization' named entity 'CD81' named entity 'antigen' named entity 'luciferase' named entity 'peptides' named entity 'HCV' named entity 'recombinant' named entity 'E2 protein' named entity 'naturally occurring' named entity 'amino acids' named entity 'amino acid' named entity 'HIV type 1' named entity 'infection' named entity 'CD81' named entity 'HCV' named entity 'Hepatitis' named entity 'expression vector' named entity 'mAb' named entity 'HCV' named entity 'San Jose' named entity 'alpha interferon' named entity 'antibody' named entity 'CD81' named entity 'transfusion' named entity 'binding site'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software